Cerebral palsy spastic children
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
2 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients 1. Clinical diagnosis of spastic cerebral palsy 2. Indication for surgical lengthening of thigh and/or calf muscles / or injections with Botuline A-Toxine in combination with a bony procedure targeting the increase of knee extension 3. Gross Motor Function Classification System Class I-III (ability to walk with or without aids) 4. Age: 6-20 years ;Patients for reliability-study 1. Clinical diagnosis of spastic cerebral palsy 2. Gross Motor Function Classification System Class I-III (ability to walk with or without aids) 3. Age: 8-16 years Control group (2 groups, for detailed description see protocol page 12/13): 1st: 1. Typically developing and healthy persons 2. Age: 6-20 years 2nd: 1. Planned surgical intervention during which harvesting of a control biopsy is possible without an additional skin incision or prolonged anaesthesia 2. Age: 6-40 years;Typically developing children for reliability study 1. Age: 6-40 years
Exclusion criteria
Exclusion criteria: Patients 1. Treatment of muscles, which are indicated for surgical procedures, with Botuline A -Toxine within three months before surgery. 2. A pre-surgical treatment with selective dorsal rhizotomy, intrathecal baclofen pump or prior surgery of treated muscle 3. Major disease or accident one year prior to measurements or a disturbed normal activity level of the child for more than three weeks in the last half year 4. 24-hour casting for more than two weeks, that includes the treated muscle three month prior to surgery 5. Additional neuromuscular, orthopaedic, inflammatory or systemic diseases which can influence walking ability or muscle properties 6. Medication that influences neuromuscular properties three month prior to surgery 7. Parents/guardians or child do not cooperate well enough to take part in the project;Patients for reliability-study & 1st Control group: Same as 1., 3. and 7. for patients;2nd control group: Sames as for patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histological, morphological and mechanical properties of the treated muscles and tendons, and angle-moment relationship | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical, gait, and functional characteristics. | — |
Countries
Netherlands
Outcome results
None listed